HIV drug could be made for just $40 a year for every patient

Generic version of a drug already on the market, which can suppress and prevent HIV, would still yield 30% profit if the current price was slashed, researchers say

A new drug described as the closest we have ever been to an HIV vaccine" could cost $40 (31) a year for every patient, a thousand times less than its current price, new research suggests.

Lenacapavir , sold as Sunlenca by US pharmaceutical giant Gilead, currently costs $42,250 for the first year. The company is being urged to make it available at a thousand times less than that price worldwide.